Wall Street analysts expect that Impax Laboratories, Inc. (NASDAQ:IPXL) will report $203.66 million in sales for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Impax Laboratories’ earnings, with the lowest sales estimate coming in at $194.60 million and the highest estimate coming in at $217.83 million. Impax Laboratories reported sales of $227.91 million during the same quarter last year, which indicates a negative year-over-year growth rate of 10.6%. The business is scheduled to issue its next quarterly earnings report before the market opens on Thursday, November 9th.

On average, analysts expect that Impax Laboratories will report full year sales of $203.66 million for the current fiscal year, with estimates ranging from $773.61 million to $810.00 million. For the next financial year, analysts forecast that the company will post sales of $888.88 million per share, with estimates ranging from $820.09 million to $988.04 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Impax Laboratories.

Impax Laboratories (NASDAQ:IPXL) last announced its earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported $0.18 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.04. The firm had revenue of $202.08 million for the quarter, compared to analyst estimates of $195.62 million. Impax Laboratories had a negative net margin of 71.08% and a positive return on equity of 9.05%. The company’s revenue for the quarter was up 17.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.21 EPS.

Several research analysts have issued reports on IPXL shares. Zacks Investment Research upgraded shares of Impax Laboratories from a “hold” rating to a “buy” rating and set a $19.00 target price on the stock in a report on Tuesday, July 11th. BidaskClub upgraded shares of Impax Laboratories from a “hold” rating to a “buy” rating in a report on Wednesday, July 12th. Royal Bank Of Canada set a $15.00 target price on shares of Impax Laboratories and gave the stock a “hold” rating in a report on Sunday, July 16th. Deutsche Bank AG set a $21.00 target price on shares of Impax Laboratories and gave the stock a “buy” rating in a report on Monday, July 17th. Finally, Piper Jaffray Companies upgraded shares of Impax Laboratories from an “underweight” rating to a “neutral” rating and increased their target price for the stock from $9.00 to $16.00 in a report on Tuesday, July 18th. Four analysts have rated the stock with a sell rating, eleven have assigned a hold rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $18.92.

Shares of Impax Laboratories (NASDAQ:IPXL) traded down 5.36% during midday trading on Thursday, hitting $18.55. 1,526,351 shares of the stock were exchanged. The firm has a 50 day moving average of $21.30 and a 200-day moving average of $17.60. Impax Laboratories has a 12 month low of $7.75 and a 12 month high of $25.70. The stock’s market cap is $1.33 billion.

Institutional investors and hedge funds have recently bought and sold shares of the business. Swiss National Bank raised its position in Impax Laboratories by 15.3% during the 2nd quarter. Swiss National Bank now owns 116,900 shares of the specialty pharmaceutical company’s stock worth $1,882,000 after buying an additional 15,500 shares during the last quarter. Great West Life Assurance Co. Can raised its position in Impax Laboratories by 3.2% during the 2nd quarter. Great West Life Assurance Co. Can now owns 106,856 shares of the specialty pharmaceutical company’s stock worth $1,715,000 after buying an additional 3,350 shares during the last quarter. BNP Paribas Arbitrage SA raised its position in Impax Laboratories by 56.4% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 23,498 shares of the specialty pharmaceutical company’s stock worth $378,000 after buying an additional 8,469 shares during the last quarter. Vanguard Group Inc. raised its position in Impax Laboratories by 4.6% during the 1st quarter. Vanguard Group Inc. now owns 6,251,395 shares of the specialty pharmaceutical company’s stock worth $79,080,000 after buying an additional 276,765 shares during the last quarter. Finally, State of Wisconsin Investment Board raised its position in Impax Laboratories by 125.1% during the 2nd quarter. State of Wisconsin Investment Board now owns 280,616 shares of the specialty pharmaceutical company’s stock worth $4,518,000 after buying an additional 155,963 shares during the last quarter. 88.68% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “$203.66 Million in Sales Expected for Impax Laboratories, Inc. (IPXL) This Quarter” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of US & international copyright law. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/26/203-66-million-in-sales-expected-for-impax-laboratories-inc-ipxl-this-quarter.html.

Impax Laboratories Company Profile

Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.

Get a free copy of the Zacks research report on Impax Laboratories (IPXL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Impax Laboratories (NASDAQ:IPXL)

Receive News & Ratings for Impax Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.